Form 8-K - Current report:
SEC Accession No. 0001140361-21-021741
Filing Date
2021-06-21
Accepted
2021-06-21 17:00:25
Documents
14
Period of Report
2021-06-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10026052_8k.htm   iXBRL 8-K 33005
2 EXHIBIT 10.1 brhc10026052_ex10-1.htm EX-10.1 118111
3 EXHIBIT 10.2(A) brhc10026052_ex10-2a.htm EX-10.2(A) 7742
  Complete submission text file 0001140361-21-021741.txt   334080

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA btx-20210616.xsd EX-101.SCH 3929
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20210616_lab.xml EX-101.LAB 22544
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20210616_pre.xml EX-101.PRE 16047
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10026052_8k_htm.xml XML 4248
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 211031559
SIC: 2834 Pharmaceutical Preparations